Working… Menu

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00776516
Recruitment Status : Completed
First Posted : October 21, 2008
Last Update Posted : July 3, 2013
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.

Condition or disease Intervention/treatment Phase
Pharmacokinetics of YM178 Drug: mirabegron Drug: rifampin Phase 1

Detailed Description:
A single group of patients will receive both mirabegron alone and in combination with rifampin

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178)
Study Start Date : October 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Experimental: 1
mirabegron alone
Drug: mirabegron
Other Name: YM178

Experimental: 2
mirabegron and rifampin
Drug: mirabegron
Other Name: YM178

Drug: rifampin
Other Name: Rifadin

Primary Outcome Measures :
  1. Assess pharmacokinetics of mirabegron alone and in combination with rifampin [ Time Frame: One month ]

Secondary Outcome Measures :
  1. Assess safety and tolerability of mirabegron alone and in combination with rifampin [ Time Frame: one month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Weighs at least 45 kg and body mass index (BMI) between 18 and 32 kg/m2 at Screening
  • Normal or not clinically significant 12 lead ECG and clinical laboratory test results at Screening
  • Female subjects must be post-menopausal, surgically sterile since at least 1 month prior to screening, or practicing effective non-hormonal contraceptive methods. All females must be non-lactating, and should have a negative result for the pregnancy test at Screening and on Day -1
  • Negative drug and alcohol screens

Exclusion Criteria:

  • Has known or suspected hypersensitivity to mirabegron or rifampin
  • Liver enzyme test abnormalities (ALT, AST, or bilirubin) above the upper limit of normal
  • History or presence of psychiatric illness, serious active or recurrent infection or hepatitis
  • Previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell carcinoma that has not been in remission for at least 5 years prior to the dose of study drug
  • Donation or loss of ≥ 450 mL blood within 56 days prior to study drug administration or has donated plasma within 7 days prior to study drug administration
  • Received or is anticipated to receive a prescription drug within 14 days prior to Day -1 or within 30 days prior to Day -1 for any long acting treatments. Use of any over-the-counter medications, including complementary and alternative medicines (except for occasional use of acetaminophen of up to 2000 mg/day but not more than 4 days per week) within 14 days prior to Day -1
  • History of substance abuse within 6 months prior to Screening
  • Current participation in another clinical trial or is taking or has been taking an investigational drug in the 30 days or 10 half lives of the drug, whichever is longer, prior to dosing
  • Known to have hepatitis or HIV-1 and/or HIV-2 or is positive for hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody at Screening
  • Subject has consumed alcohol, caffeine-containing food or beverages, grapefruit juice, grapefruit-containing products or Seville oranges within 48 prior to Day -1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00776516

Layout table for location information
United States, Florida
Miami, Florida, United States, 33126
Sponsors and Collaborators
Astellas Pharma Inc
Layout table for investigator information
Study Director: Central Contact Astellas Pharma Global Development
Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Inc Identifier: NCT00776516    
Other Study ID Numbers: 178-CL-070
First Posted: October 21, 2008    Key Record Dates
Last Update Posted: July 3, 2013
Last Verified: July 2013
Keywords provided by Astellas Pharma Inc:
Healthy volunteer subjects
CYP3A4 inducer
drug interaction
Additional relevant MeSH terms:
Layout table for MeSH terms
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Urological Agents